Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) presented findings at the Heart Failure Society of America Annual Scientific Meeting, indicating that increased mortality risk correlates with worsening New York Heart Association (NYHA) functional class among patients with obstructive hypertrophic cardiomyopathy (HCM). The study, involving 2,495 patients, showed varying mortality rates: 5% for NYHA class I, 9% for class II, and 13% for class III/IV over a median follow-up of 3.9 years. These results underscore the importance of assessing NYHA class in treatment outcomes.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on November 1, 2021, to stockholders of record by October 1, 2021. Additionally, a dividend of $0.50 per share will be paid on its convertible preferred stock on December 1, 2021, for stockholders of record by November 9, 2021. This reflects the company's commitment to returning value to shareholders.
Bristol Myers Squibb (NYSE:BMY) will release its third quarter 2021 financial results on
Bristol Myers Squibb (NYSE:BMY) employee Mark DeLong is participating in the Coast 2 Coast 4 Cancer cycling event, aiming to raise over
Bristol Myers Squibb (NYSE: BMY) announced significant data on immunotherapies at ESMO 2021, showcasing long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) in advanced cancers. Five-year results from CheckMate-214 in renal cell carcinoma and three-year updates from CheckMate-743 in malignant pleural mesothelioma highlight the effectiveness of these treatments. Additional data on the LAG-3 blocking antibody relatlimab combined with nivolumab emphasizes its potential in treating metastatic melanoma. These findings reinforce the role of these therapies in improving patient outcomes.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Virtual Conference on September 14, 2021, at 8 a.m. ET. Giovanni Caforio, M.D., the CEO, will answer questions about the company during this session. Investors and the public can access the live webcast at investor.bms.com, with an archived version available later that day.
Bristol Myers Squibb (NYSE:BMY) announced that the FDA has accepted its supplemental Biologics License Application for Orencia (abatacept) aimed at preventing acute graft versus host disease (aGvHD) in patients 6 years and older undergoing unrelated donor stem cell transplants. The FDA granted Priority Review, with a PDUFA goal date set for December 23, 2021. The application is backed by results from the Phase 2 ABA2 trial, which showed that Orencia significantly reduced aGvHD severity without increasing disease relapse rates.
Bristol Myers Squibb (NYSE: BMY) announced that the FDA approved Opdivo (nivolumab) for the adjuvant treatment of high-risk urothelial carcinoma (UC) patients post-radical resection. The approval stems from the Phase 3 CheckMate -274 trial, where Opdivo significantly improved median disease-free survival (DFS) compared to placebo (20.8 vs. 10.8 months). Notably, Opdivo reduced the recurrence or death risk by 30%. This marks the third cancer type where Opdivo is the first PD-1 inhibitor approved for adjuvant use, addressing a significant unmet need in UC treatment.
Bristol Myers Squibb (NYSE: BMY) has received Conditional Marketing Authorization from the European Commission for Abecma (idecabtagene vicleucel), a first-in-class CAR T cell therapy for adult patients with relapsed and refractory multiple myeloma. This therapy targets B-cell maturation antigen (BCMA) and is approved for patients who have undergone at least three prior treatments. With an overall response rate of 73% from clinical trials, Abecma provides a new treatment option for those with limited alternatives, addressing a significant unmet medical need in Europe.
Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency (EMA) has validated its Type II Variation Marketing Authorization Applications for Opdivo in combination with Yervoy and chemotherapy as first-line treatments for unresectable advanced esophageal squamous cell carcinoma (ESCC). This validation confirms the completeness of the applications and initiates the EMA's review process. The applications are based on the impressive results from the Phase 3 CheckMate -648 trial, demonstrating significant overall survival benefits for patients treated with these combinations.